Premium
Treatment of primary CNS lymphoma with high‐dose methotrexate in immunocompetent pediatric patients
Author(s) -
Shah Amish C.,
Kelly David R.,
Nabors L. Burt,
Oakes W. Jerry,
Hilliard Lee M.,
Reddy Alyssa T.
Publication year - 2010
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.22752
Subject(s) - medicine , methotrexate , radiation therapy , lymphoma , disease , primary central nervous system lymphoma , oncology , chemotherapy
We report two cases of primary CNS lymphoma (PCNSL) treated with high‐dose methotrexate. Though standard adult treatment of PCNSL incorporates whole‐brain radiotherapy, the literature suggests it may be possible to delay or avoid radiotherapy and the associated increased risk of neurologic sequelae in pediatric patients. Studies in adults indicate methotrexate therapy can be effective against PCNSL and has advantages over the current standard of treatment. Both patients have no evidence of disease 9 and 7 years after treatment, suggesting high‐dose methotrexate may lead to disease control in pediatric patients with PCNSL while avoiding the effects of radiotherapy. Pediatr Blood Cancer. 2010;55:1227–1230. © 2010 Wiley‐Liss, Inc.